16:25 , Feb 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; breast cancer; colorectal cancer Mouse studies suggest intratumoral injection of a TLR9 agonist and an agonist antibody against OX40 could help treat lymphoma, breast cancer and colorectal cancer. In a mouse model of...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

IMO-2055: Phase Ib data

Data from 15 patients with colorectal cancer who progressed following chemotherapy for advanced or metastatic disease in an open-label, dose-escalation, U.S. Phase Ib trial showed that once-weekly subcutaneous injections of 0.16, 0.32 and 0.48 mg/kg...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

IMO-2055: Phase II data

Top-line data from an open-label, international Phase II trial in 106 patients with recurrent or metastatic SCCHN who were naïve to Erbitux cetuximab showed that once-weekly subcutaneous 0.32 mg/kg IMO-2055 plus Erbitux missed the primary...
07:00 , May 7, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $1.33 (11%) to $13.77 last week after FDA accepted for review an NDA for lomitapide to treat homozygous familial hypercholesterolemia. The PDUFA date is Dec. 29. Alexza Pharmaceuticals...
00:39 , May 4, 2012 |  BC Extra  |  Clinical News

Idera's IMO-2055 misses SCCHN endpoint

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) said once-weekly subcutaneous IMO-2055 plus Erbitux cetuximab missed the primary endpoint of median progression-free survival (PFS) vs. Erbitux alone in a Phase II trial to treat recurrent or metastatic squamous cell...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Clinical News

IMO-2055: Additional Phase Ib data

Additional data from an open-label, dose-escalation, U.S. Phase Ib trial in 33 evaluable patients with advanced NSCLC who failed >=1 prior course of chemotherapy showed that subcutaneous IMO-2055 plus Tarceva erlotinib and Avastin bevacizumab led...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Idera, Merck KGaA deal

Idera regained rights to cancer product IMO-2055 following the termination of a 2007 deal with Merck. In July, Idera said Merck would not conduct further development of IMO-2055 after an increased incidence of neutropenia and...
01:27 , Dec 1, 2011 |  BC Extra  |  Company News

Idera up as IMO-2055 deal ends

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) gained $0.17 (15%) to $1.31 on Wednesday as it regained rights to cancer product IMO-2055 following the termination of a 2007 deal with Merck KGaA (Xetra:MRK). In July, Idera said Merck...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Few Cinderellas this time

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Clinical News

IMO-2055: Development discontinued

Idera said Merck will not conduct further development of IMO-2055 to treat cancer after an increased incidence of neutropenia and electrolyte imbalances were reported in a Phase Ib trial of the compound in combination with...